FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285588894> ?p ?o ?g. }

• W4285588894 abstract "Abstract Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical practice are largely unknown. To answer this question, we performed a multicenter (25 US centers) cohort study and divided the study population into three groups: “ibrutinib responders”—patients who achieved complete or partial response (CR/PR) to ibrutinib; “stable disease (SD)”; and “primary progressors (PP)”—patients with progression of disease as their best response to ibrutinib. One hundred and nineteen patients met the eligibility criteria with 58%/17% ORR/CR, 29% with SD, and 13% with PP. The median PFS and OS were 29 and 71.4 months, respectively, with no difference in PFS or OS based on the ibrutinib line of therapy or type of therapy before ibrutinib. Patients with complex cytogenetics had an inferior PFS (HR = 3.08, 95% CI 1.23–7.67, p = 0.02), while those with both complex cytogenetics (HR = 3.00, 95% CI 1.03–8.68, p = 0.04) and PP (HR = 13.94, 95% CI 5.17–37.62, p < 0.001) had inferior OS. Only primary refractory disease to first-line therapy predicted a higher probability of PP to ibrutinib (RR = 3.77, 95% CI 1.15–12.33, p = 0.03). In this largest study to date evaluating outcomes of R/R MZL treated with ibrutinib, we show that patients with primary refractory disease and those with PP on ibrutinib are very high-risk subsets and need to be prioritized for experimental therapies." @default.
• W4285588894 created "2022-07-16" @default.
• W4285588894 creator A5000227859 @default.
• W4285588894 creator A5001117158 @default.
• W4285588894 creator A5005446802 @default.
• W4285588894 creator A5007477825 @default.
• W4285588894 creator A5010681953 @default.
• W4285588894 creator A5012121701 @default.
• W4285588894 creator A5013241767 @default.
• W4285588894 creator A5013561584 @default.
• W4285588894 creator A5013911840 @default.
• W4285588894 creator A5015875316 @default.
• W4285588894 creator A5016048836 @default.
• W4285588894 creator A5017559837 @default.
• W4285588894 creator A5018812950 @default.
• W4285588894 creator A5019666650 @default.
• W4285588894 creator A5020537159 @default.
• W4285588894 creator A5023403620 @default.
• W4285588894 creator A5024909755 @default.
• W4285588894 creator A5029491549 @default.
• W4285588894 creator A5030788778 @default.
• W4285588894 creator A5033965805 @default.
• W4285588894 creator A5040342262 @default.
• W4285588894 creator A5048939308 @default.
• W4285588894 creator A5049706288 @default.
• W4285588894 creator A5050068696 @default.
• W4285588894 creator A5050643493 @default.
• W4285588894 creator A5056871721 @default.
• W4285588894 creator A5058210944 @default.
• W4285588894 creator A5058222563 @default.
• W4285588894 creator A5059317772 @default.
• W4285588894 creator A5059854479 @default.
• W4285588894 creator A5062329931 @default.
• W4285588894 creator A5064423861 @default.
• W4285588894 creator A5069873622 @default.
• W4285588894 creator A5071938732 @default.
• W4285588894 creator A5074766331 @default.
• W4285588894 creator A5075085884 @default.
• W4285588894 creator A5078508615 @default.
• W4285588894 creator A5079899240 @default.
• W4285588894 creator A5082107104 @default.
• W4285588894 creator A5085325467 @default.
• W4285588894 creator A5085565650 @default.
• W4285588894 creator A5087097104 @default.
• W4285588894 creator A5087749554 @default.
• W4285588894 creator A5088169139 @default.
• W4285588894 creator A5091299708 @default.
• W4285588894 date "2022-07-16" @default.
• W4285588894 modified "2023-10-14" @default.
• W4285588894 title "Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study" @default.
• W4285588894 cites W2310716991 @default.
• W4285588894 cites W2518731208 @default.
• W4285588894 cites W2587684973 @default.
• W4285588894 cites W2900472144 @default.
• W4285588894 cites W3107020624 @default.
• W4285588894 cites W3143994784 @default.
• W4285588894 doi "https://doi.org/10.1186/s13045-022-01316-1" @default.
• W4285588894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35842643" @default.
• W4285588894 hasPublicationYear "2022" @default.
• W4285588894 type Work @default.
• W4285588894 citedByCount "1" @default.
• W4285588894 countsByYear W42855888942023 @default.
• W4285588894 crossrefType "journal-article" @default.
• W4285588894 hasAuthorship W4285588894A5000227859 @default.
• W4285588894 hasAuthorship W4285588894A5001117158 @default.
• W4285588894 hasAuthorship W4285588894A5005446802 @default.
• W4285588894 hasAuthorship W4285588894A5007477825 @default.
• W4285588894 hasAuthorship W4285588894A5010681953 @default.
• W4285588894 hasAuthorship W4285588894A5012121701 @default.
• W4285588894 hasAuthorship W4285588894A5013241767 @default.
• W4285588894 hasAuthorship W4285588894A5013561584 @default.
• W4285588894 hasAuthorship W4285588894A5013911840 @default.
• W4285588894 hasAuthorship W4285588894A5015875316 @default.
• W4285588894 hasAuthorship W4285588894A5016048836 @default.
• W4285588894 hasAuthorship W4285588894A5017559837 @default.
• W4285588894 hasAuthorship W4285588894A5018812950 @default.
• W4285588894 hasAuthorship W4285588894A5019666650 @default.
• W4285588894 hasAuthorship W4285588894A5020537159 @default.
• W4285588894 hasAuthorship W4285588894A5023403620 @default.
• W4285588894 hasAuthorship W4285588894A5024909755 @default.
• W4285588894 hasAuthorship W4285588894A5029491549 @default.
• W4285588894 hasAuthorship W4285588894A5030788778 @default.
• W4285588894 hasAuthorship W4285588894A5033965805 @default.
• W4285588894 hasAuthorship W4285588894A5040342262 @default.
• W4285588894 hasAuthorship W4285588894A5048939308 @default.
• W4285588894 hasAuthorship W4285588894A5049706288 @default.
• W4285588894 hasAuthorship W4285588894A5050068696 @default.
• W4285588894 hasAuthorship W4285588894A5050643493 @default.
• W4285588894 hasAuthorship W4285588894A5056871721 @default.
• W4285588894 hasAuthorship W4285588894A5058210944 @default.
• W4285588894 hasAuthorship W4285588894A5058222563 @default.
• W4285588894 hasAuthorship W4285588894A5059317772 @default.
• W4285588894 hasAuthorship W4285588894A5059854479 @default.
• W4285588894 hasAuthorship W4285588894A5062329931 @default.
• W4285588894 hasAuthorship W4285588894A5064423861 @default.
• W4285588894 hasAuthorship W4285588894A5069873622 @default.
• W4285588894 hasAuthorship W4285588894A5071938732 @default.
• W4285588894 hasAuthorship W4285588894A5074766331 @default.
• W4285588894 hasAuthorship W4285588894A5075085884 @default.
• W4285588894 hasAuthorship W4285588894A5078508615 @default.

• next